Expert Interviews on Treatment of Multiple Sclerosis: Shifting the Paradigm in 2015 will equips the attendee with new research in MS pathology and treatment, and also discusses significant differences in the disease and management of patients with progressive forms of MS. Treatment with disease modifying therapies (DMTs) can alter the otherwise debilitating course of multiple sclerosis (MS), a progressive, inflammatory, autoimmune disease of the central nervous system. For persons with established disease, DMTs are aimed toward lowering the amount and harshness of clinical attacks, delaying the onset of disability, and lowering number of lesions within the brain and spinal cord. Over the last several decades, treatment options have been designed for their effect on T cells in the pathogenesis of MS. However, modern data has revealed that B cells and humoral immunity also have an vital role in MS pathogenesis, which is leading to advanced treatment options. With an extensive body of evidence and fresh therapies emerging it is important that clinicians be fluent in up and coming safety, efficacy, and tolerability data as it correleates to existing and investigational agents.